G42 Healthcare Strengthens Clinical Genomics Offering with Saphetor’s VarSome Bioinformatics Platform, Strengthens UAE’s Position as Global Leader in Healthcare Innovation

ABU DHABI, United Arab Emirates–(BUSINESS WIRE)–In a move aimed at enhancing its clinical genomics capabilities in the region and beyond, G42 Healthcare, Abu Dhabi-based leading AI healthcare technology company has announced a partnership with Saphetor SAa Swiss precision medicine company and creator of the VarSome suite of bioinformatics solutions.

The collaboration is a key step in G42 Healthcare’s strategy to support the health of future generations, in addition to strengthening the UAE’s reputation as a hub for global innovation and clinical genomics research.

Saphetor’s VarSome Clinical – a clinically certified cloud-based platform enabling rapid and accurate variant discovery, annotation and interpretation of next-generation sequencing data – complements G42 Healthcare’s robust capabilities for faster and more accurate sequencing data, helping biologists, geneticists and physicians to push the boundaries of innovation and discovery in healthcare.

Advancing these new capabilities is part of G42 Healthcare’s mission to provide insights and facilitate early diagnosis and treatment of cancer, rare and metabolic diseases and other genetic diseases in the region. The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies with the shortest turnaround times. This collaboration also enables clinical genomics, at scale, as a service using G42 Healthcare’s 3 genome sequencing platforms offering both long and short read capabilities.

VarSome Clinical’s accurate variant calling and world-leading variant annotation and classification capabilities combined with Saphetor’s sophisticated deployment capabilities make it ideally suited for G42 Healthcare to address the stringent data regulations in place in the region for genomic data.

Commenting on the partnership, Ashish Koshy said, “G42 Healthcare is committed to pushing the boundaries of innovation to enable us to continuously offer innovative solutions across the entire healthcare value chain. The collaboration will strengthen G42 Healthcare’s clinical genomics solutions by leveraging the VarSome suite of bioinformatics tools to deliver valuable insights and improved outcomes. This partnership is a key step in our efforts to strengthen the UAE’s reputation as a regional hub for healthcare and life sciences innovation.”

Andreas Masouras, CEO and founder of Saphetor SA, said: “Since its inception, Saphetor has been committed to enabling accurate molecular diagnostics at scale for a wide range of diseases by identifying and interpreting human genomic variants using proprietary algorithms and expert knowledge in the field. VarSome is an extremely valuable resource for clinical decision support as well as for clinical genomic research to provide comprehensive genome data, biological insights and healthcare outcomes for better personalized and preventive healthcare delivery. At Saphetor, we are all excited about our technology that will serve the people of the UAE and beyond through our partnership with G42 Healthcare”.

VarSome Clinical is powered by a comprehensive molecular database of 140 curated and aggregated genomic data sources and is further supported by an extensive library of related publications and commentary from a global community of over 500,000 VarSome.com users. The platform applies recognized global standards for germline and somatic variant interpretation to create real-time pathogenicity classifications.

G42 Healthcare has built the largest Omics Center of Excellence in the region, which uses advanced short- and long-read sequencing technologies, making it a preferred partner for governments, research institutes, hospitals and omics centers. This capability helps G42 Healthcare offer state-of-the-art clinical genetic sequencing services across the disease spectrum, from acute to chronic to lifestyle.


About G42 Healthcare

G42 Healthcare, a leading healthcare technology company, is on a mission to develop a world-class healthcare sector in the UAE and beyond by leveraging data and advanced medical technologies to unlock the potential of personalized and preventive care and transform the traditional healthcare ecosystem. We built Biogenix Labs, the first accredited COVID-19 large-scale laboratory in the UAE, facilitated the clinical trials of 4Humanity, the world’s first phase three trial of an inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities in the Pan-Arab region, created the region’s first dedicated contract research organization (IROS) to conduct clinical research with and for the local population, supported the UAE health authorities in the implementation of national vaccination, conducted research into new vaccines and drug therapies, and built the Omics Center of Excellence, the largest and a technologically advanced Omics facility in the region that is the backbone of the Emirati Genome Programme, the most comprehensive population genomics initiative in the world.

For further information on G42 Healthcare visit https://www.g42healthcare.ai

About Saphetor SA

Saphetor SA is a global precision medicine company dedicated to large-scale identification and interpretation of human genetic variants using proprietary algorithms and domain expertise.

Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions for both clinicians and researchers. VarSome.com’s professional community and search engine are freely available, featuring a widely recognized community-driven knowledge base that enables flexible querying in more than 140 resources for genetic and genomic data.

VarSome Premium and VarSome Clinical are professional editions of VarSome with powerful functionality and additional advanced data mining and analysis tools. VarSome Clinical is a CE-IVD-certified and HIPAA-compliant platform enabling rapid and accurate variant discovery, annotation and interpretation of NGS data for whole genomes, exomes and gene panels, helping clinicians reach faster and more accurate diagnoses and treatment solutions for genetic conditions. VarSome can also be integrated into existing internal pipelines via the VarSome API via cloud-based or on-premises installations.

Leave a Comment